Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorKayigire, Xavier A.
dc.contributor.authorFriedrich, Sven O.
dc.contributor.authorVenter, Amour
dc.contributor.authorDawson, Rodney
dc.contributor.authorGillespie, Stephen Henry
dc.contributor.authorBoeree, Martin J.
dc.contributor.authorHeinrich, Norbert
dc.contributor.authorHoelscher, Michael
dc.contributor.authorDiacon, Andreas H.
dc.date.accessioned2014-08-25T14:01:00Z
dc.date.available2014-08-25T14:01:00Z
dc.date.issued2013-04
dc.identifier.citationKayigire , X A , Friedrich , S O , Venter , A , Dawson , R , Gillespie , S H , Boeree , M J , Heinrich , N , Hoelscher , M & Diacon , A H 2013 , ' Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity ' , Journal of Clinical Microbiology , vol. 51 , no. 6 , pp. 1894-1898 . https://doi.org/10.1128/JCM.03290-12en
dc.identifier.issn0095-1137
dc.identifier.otherPURE: 64212449
dc.identifier.otherPURE UUID: 21b80800-2e10-4ee5-a168-3fcbbbe4924b
dc.identifier.otherWOS: 000319197800036
dc.identifier.otherScopus: 84878517180
dc.identifier.otherORCID: /0000-0001-6537-7712/work/39477852
dc.identifier.urihttp://hdl.handle.net/10023/5223
dc.descriptionThis study was conducted as an activity of the Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). PanACEA is funded by EDCTP grants CT.2004.32011.001, IP.2007.32011.011, IP.2007.32011.012, and IP.2007.32011.013, the Bill and Melinda Gates Foundation, the UK Medical Research Council, and the German Ministry of Science and Technology (BmBF; grant 01KA0901). A specific Ph.D. stipend was given by PanACEA to X. A. Kayigire to foster local career development.en
dc.description.abstractThe early bactericidal activity of antituberculosis agents is usually determined by measuring the reduction of the sputum mycobacterial load over time on solid agar medium or in liquid culture. This study investigated the value of a quantitative PCR assay for early bactericidal activity determination. Groups of 15 patients were treated with 6 different antituberculosis agents or regimens. Patients collected sputum for 16 h overnight at baseline and at days 7 and 14 after treatment initiation. We determined the sputum bacterial load by CFU counting (log CFU/ml sputum, reported as mean ± standard deviation [SD]), time to culture positivity (TTP, in hours [mean ± SD]) in liquid culture, and Xpert MTB/RIF cycle thresholds (TC, n [mean ± SD]). The ability to discriminate treatment effects between groups was analyzed with one-way analysis of variance (ANOVA). All measurements showed a decrease in bacterial load from mean baseline (log CFU, 5.72 ± 1.00; TTP, 116.0 ± 47.6; TC, 19.3 ± 3.88) to day 7 (log CFU, −0.26 ± 1.23, P = 0.2112; TTP, 35.5 ± 59.3, P = 0.0002; TC, 0.55 ± 3.07, P = 0.6030) and day 14 (log CFU, −0.55 ± 1.24, P = 0.0006; TTP, 54.8 ± 86.8, P < 0.0001; TC, 2.06 ± 4.37, P = 0.0020). The best discrimination between group effects was found with TTP at day 7 and day 14 (F = 9.012, P < 0.0001, and F = 11.580, P < 0.0001), followed by log CFU (F = 4.135, P = 0.0024, and F = 7.277, P < 0.0001). TC was not significantly discriminative (F = 1.995, P = 0.091, and F = 1.203, P = 0.316, respectively). Culture-based methods are superior to PCR for the quantification of early antituberculosis treatment effects in sputum.
dc.format.extent5
dc.language.isoeng
dc.relation.ispartofJournal of Clinical Microbiologyen
dc.rightsCopyright © 2013, American Society for Microbiology. All Rights Reserved.en
dc.subjectPulmonary tuberculosisen
dc.subjectRifampin resistanceen
dc.subjectTimeen
dc.subjectQR Microbiologyen
dc.subject.lccQRen
dc.titleDirect comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activityen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Medicineen
dc.contributor.institutionUniversity of St Andrews.Gillespie Groupen
dc.contributor.institutionUniversity of St Andrews.Biomedical Sciences Research Complexen
dc.contributor.institutionUniversity of St Andrews.Global Health Implementation Groupen
dc.contributor.institutionUniversity of St Andrews.Infection Groupen
dc.identifier.doihttps://doi.org/10.1128/JCM.03290-12
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record